Legend Biotech Corporation (LEGN) Stock Chart

NasdaqGS
$19.27-2.95 (-13.28%)

View the Legend Biotech Corporation stock chart with market data, key statistics, volume, financial metrics, latest news, and exportable historical data.

Source
Nasdaq Real Time Price
Quote Time
Jul 27, 2026, 8:00 PM UTC
Delay
No source-reported delay

Market data is for research and educational use only, not investment advice. Quotes may be delayed depending on the source and exchange; verify important prices with your broker or data provider.

Read the LEGN trend first

Use the range controls to compare short-term moves with the longer-term Legend Biotech Corporation stock chart. A move that looks large on 1D can look routine on a 1Y or 5Y chart.

Check price with volume

Volume helps show whether a move happened with broad participation or thin trading. Compare recent bars with the average volume and news context before drawing conclusions.

Verify before acting

This page is built for research and education. Quotes, analyst fields, and news can be delayed or revised, so verify important prices with your broker or primary data provider.

Key Statistics

Previous Close$22.22
Open$20.55
Day Range$18.64 — $20.74
52 Wk Range$16.24 — $43.71
Volume10,062,494
Avg Volume2,625,727
Market Cap3.73B
P/E (TTM)
P/E (Fwd)17.56
EPS (TTM)$-1.38
Dividend Yield
Beta0.34
50 Day Avg$28.83
200 Day Avg$24.87
Shares Out193.44M
PEG Ratio
Price/Book3.70

Financial Metrics

Revenue
1.14B
Revenue Growth
56.50%
Gross Margin
54.99%
Operating Margin
-16.32%
Profit Margin
-21.96%
Return on Equity
-25.19%
Total Cash
834.60M
Total Debt
389.30M
Free Cash Flow
-55.77M
Analyst Target
$54.23
Analyst Consensus
Buy
Analyst Opinions
15

About Legend Biotech Corporation

Sector
Healthcare
Industry
Biotechnology
Employees
3,100
Headquarters
Somerset, NJ, United States
CEO
Dr. Ying Huang Ph.D.

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.

Related Charts

Data Definitions

Previous close

The most recent prior regular-session close reported by the market data source.

Day range

The source-reported high and low for the current or most recent trading session.

Volume

The number of shares, units, contracts, or asset quantity reported as traded during the period.

Moving averages

The 50-day and 200-day averages smooth recent prices to give quick trend context.

Market cap

A company or fund size estimate based on price and shares outstanding when source data is available.

P/E ratio

Price divided by earnings per share. It is most useful when compared with peers and growth expectations.